US Bioservices now dispenses HEMLIBRA

The U.S. Food and Drug Administration has approved HEMLIBRA (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors.